FDA’s Opdivo Lung Cancer Approval

By João L. Carapinha

October 11, 2024

The FDA has approved a new treatment regimen using Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC), marking a significant advancement in cancer care. This approval paves the way for adult patients with resectable NSCLC to receive a combination of Opdivo and platinum-doublet chemotherapy as a neoadjuvant therapy, followed by surgery, and then adjuvant single-agent Opdivo. This targeted approach is for patients who do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) rearrangements.

Approval Details

The FDA has approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by surgery, and then adjuvant single-agent Opdivo for adult patients with resectable NSCLC. This approval specifically targets patients without EGFR or ALK rearrangements.

Clinical Trial

The approval is based on the results of the Phase III CheckMate-77T trial, a randomized, double-blind, multi-center study. The trial involved 461 patients and compared neoadjuvant Opdivo with platinum-doublet chemotherapy followed by surgery and adjuvant single-agent Opdivo against neoadjuvant platinum-doublet chemotherapy and placebo followed by surgery and adjuvant placebo.

Efficacy

Results demonstrated that the combination of Opdivo with chemotherapy significantly enhanced event-free survival (EFS) and pathologic complete response (pCR) compared to chemotherapy alone. Notably, the median EFS was not reached in the nivolumab arm, while it stood at 18.4 months in the chemotherapy arm (HR, 0.58; 95% CI, 0.43-0.78; P = 0.00025).

Safety

Adverse events (AEs) were comparable to those seen in previous clinical trials involving nivolumab and chemotherapy. A small portion of patients treated with nivolumab experienced delays in surgery or were unable to undergo the procedure due to AEs.

Clinical Implications

This FDA approval represents a critical step in addressing the treatment needs of patients requiring therapies before and after surgery to target micrometastasis, lower the risk of cancer recurrence, and enhance surgical success. This regimen holds promise for improved EFS and may lead to a pCR in one out of four patients.

Expanded Role of Opdivo

The FDA’s decision expands the role of Opdivo-based treatments, building upon prior approvals for neoadjuvant-only Opdivo plus chemotherapy for resectable NSCLC, as demonstrated in the CheckMate-816 trial. This reinforces Bristol Myers Squibb’s commitment to enhancing patient outcomes and broadening its thoracic portfolio in early-stage diseases, with Opdivo now playing a pivotal role in treatment protocols for resectable NSCLC.

Reference url

Recent Posts

Argentina WHO Withdrawal
   

Argentina WHO Withdrawal: President Milei Exits Global Health Alliance Amid COVID-19 Disputes

💡 *What happens when a country decides to withdraw from global health organizations?*
Argentina’s President Javier Milei has made the bold move to withdraw from the WHO, citing significant disagreements over health management during the pandemic. This decision raises questions about national sovereignty, cooperation, and the future of global health initiatives. Dive into the implications of Argentina’s stance and what it means for international health governance.

#SyenzaNews #globalhealth #healthcarepolicy

Gauteng HPV vaccination campaign
      

Gauteng HPV Vaccination Campaign: Protecting Girls Against Cervical Cancer

💉 Ready to protect our future generations from cervical cancer?

The Gauteng HPV vaccination campaign aims to vaccinate grade 5, 6, and 7 girls against the virus that causes most cervical cancers. By leveraging a single-dose regimen, this initiative not only enhances access to life-saving vaccines but also strives to meet ambitious global health targets.

Explore how this campaign is reshaping health outcomes in South Africa and why parental consent is key to its success.

#SyenzaNews #HealthEconomics #HealthcareInnovation #UniversalHealthCoverage

Capvaxive vaccine approval
     

Capvaxive Vaccine Approval

🌍 What if a single vaccine could significantly change the landscape of pneumococcal disease prevention in adults?

The European Medicines Agency has just recommended Merck’s Capvaxive, an innovative 21-valent pneumococcal conjugate vaccine! With robust data from multiple phase 3 trials, this potential approval marks a pivotal step in the fight against invasive Streptococcus pneumoniae infections in the EU. Look into how Capvaxive could enhance public health outcomes and offer extensive serotype coverage.

#SyenzaNews #pharmaceuticals #healthcarepolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.